Cyclophosphamide-associated bladder cancers and considerations for survivorship care: A systematic review.

[1]  M. Galsky,et al.  What Is the Significance of Variant Histology in Urothelial Carcinoma? , 2020, European urology focus.

[2]  A. Diallo,et al.  Non-Muscle Invasive Bladder Cancer: A Review of the Current Trend in Africa , 2019, World journal of oncology.

[3]  Yair Lotan,et al.  Treatment of Non‐Metastatic Muscle‐Invasive Bladder Cancer: AUA/ASCO/ASTRO/SUO Guideline , 2017, The Journal of urology.

[4]  M. Hsieh,et al.  Review of Advances in Uroprotective Agents for Cyclophosphamide- and Ifosfamide-induced Hemorrhagic Cystitis. , 2017, Urology.

[5]  J. Chan,et al.  Cyclophosphamide in dermatology , 2017, The Australasian journal of dermatology.

[6]  Y. Lotan,et al.  Gender and Bladder Cancer: A Collaborative Review of Etiology, Biology, and Outcomes. , 2016, European urology.

[7]  A. Voss,et al.  Prolonged risk of specific malignancies following cyclophosphamide therapy among patients with granulomatosis with polyangiitis. , 2015, Rheumatology.

[8]  I. Cullen,et al.  Intermittent self-catheterization and the risk of squamous cell cancer of the bladder: An emerging clinical entity? , 2013, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.

[9]  L. Marchionni,et al.  An EGFR-ERK-SOX9 signaling cascade links urothelial development and regeneration to cancer. , 2011, Cancer research.

[10]  J. Cheville,et al.  Leiomyosarcoma of the urinary bladder: a clinicopathological study of 34 cases , 2010, Journal of Clinical Pathology.

[11]  J. Harbour,et al.  Review of 676 second primary tumors in patients with retinoblastoma: association between age at onset and tumor type. , 2010, Archives of ophthalmology.

[12]  B. Norlén,et al.  Recurrence, progression and survival in bladder cancer. A retrospective analysis of 232 patients with greater than or equal to 5-year follow-up. , 2010, Scandinavian journal of urology and nephrology.

[13]  Ashkan Emadi,et al.  Cyclophosphamide and cancer: golden anniversary , 2009, Nature Reviews Clinical Oncology.

[14]  Y. Lotan,et al.  Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy. , 2009, European urology.

[15]  V. Tesar,et al.  Pulse Versus Daily Oral Cyclophosphamide for Induction of Remission in Antineutrophil Cytoplasmic AntibodyAssociated Vasculitis , 2009, Annals of Internal Medicine.

[16]  D. Parekh,et al.  Leiomyosarcoma in urinary bladder after cyclophosphamide therapy for retinoblastoma and review of bladder sarcomas. , 2002, Urology.

[17]  L. Comunale,et al.  Leiomyosarcoma of the Bladder Fourteen Years After Cyclophosphamide Therapy for Retinoblastoma , 2001 .

[18]  T. Nakamoto,et al.  Invasive bladder cancer after cyclophosphamide administration for nephrotic syndrome--a case report. , 2000, Hiroshima journal of medical sciences.

[19]  M. Nahata,et al.  Cardiotoxicity of Chemotherapeutic Agents , 2000 .

[20]  H. Poppel,et al.  Bladder cancer in patients with multiple sclerosis treated with cyclophosphamide. , 1998, The Journal of urology.

[21]  D. Bostwick,et al.  Carcinosarcoma and sarcomatoid carcinoma of the bladder: clinicopathological study of 41 cases. , 1998, The Journal of urology.

[22]  R. Tarone,et al.  p53 mutations in cyclophosphamide-associated bladder cancer. , 1998, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[23]  Guy Hoffman,et al.  Cyclophosphamide-Induced Cystitis and Bladder Cancer in Patients with Wegener Granulomatosis , 1996, Annals of Internal Medicine.

[24]  N. Day,et al.  Bladder tumours following chemotherapy and radiotherapy for ovarian cancer: A case—control study , 1995, International journal of cancer.

[25]  A. Hagenbeek,et al.  Bladder and kidney cancer following cyclophosphamide therapy for non-Hodgkin's lymphoma. , 1995, Journal of the National Cancer Institute.

[26]  A. Steinberg,et al.  Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis , 1992, The Lancet.

[27]  R. Dorr,et al.  Chemoprotectants for cancer chemotherapy. , 1991, Seminars in oncology.

[28]  P. Hartge,et al.  Epidemiological characteristics of squamous cell carcinoma and adenocarcinoma of the bladder. , 1988, Cancer research.

[29]  D. Schmähl,et al.  Prevention of cyclophosphamide-induced carcinogenesis in the urinary bladder of rats by administration of mesna. , 1983, Cancer treatment reviews.

[30]  M. Habs,et al.  Prevention of urinary bladder tumors in cyclophosphamide‐treated rats by additional medication with the uroprotectors sodium 2‐mercaptoethane sulfonate (mesna) and disodium 2,2′‐dithio‐bis‐ethane sulfonate (dimesna) , 1983, Cancer.

[31]  D. Schmähl,et al.  Carcinogenic action of low‐dose cyclophosphamide given orally to sprague‐dawley rats in a lifetime experiment , 1979, International journal of cancer.

[32]  M. Soloway,et al.  Does cyclophosphamide induce bladder cancer? , 1978, Urology.

[33]  G. Moberger,et al.  Classification of bladder tumours based on the cellular pattern. Preliminary report of a clinical-pathological study of 300 cases with a minimum follow-up of eight years. , 1965, Acta chirurgica Scandinavica.

[34]  P. Merkel,et al.  Incidence and prevention of bladder toxicity from cyclophosphamide in the treatment of rheumatic diseases: a data-driven review. , 2010, Arthritis and rheumatism.

[35]  E. Hurd,et al.  The effect of cyclophosphamide on B and T lymphocytes in patients with connective tissue diseases. , 1975, Arthritis and rheumatism.